title: Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.
abstract: OBJECTIVE
  To examine the effect of adjuvant chemoradiation for adenocarcinoma of the distal common bile duct (DCBD) after pancreaticoduodenectomy (PD) on local control and survival.
  
  
  METHODS
  A total of 34 cases of adenocarcinoma of the DCBD were treated with PD and adjuvant chemoradiation at Johns Hopkins Hospital between 1994 and 2003. Median radiation dose was 5,040 cGy (range, 4,000-5,400 cGy). Concurrent 5-fluorouracil-based chemotherapy was given with radiation therapy, followed by maintenance chemotherapy.
  
  
  RESULTS
  The median follow-up of patients alive at the time of analysis was 41 months. Death occurred in 21 of 34 patients (62%) during the follow-up period, all from progressive, distant metastatic disease. Median overall survival was 36.9 months, with a 5-year survival of 35%. On multivariate analysis, only nodal status significantly predicted survival (p < 0.02). For patients with negative and positive lymph nodes, 5-year survival was 100% and 24%, respectively. Actuarial 5-year local control was 70%. Compared with historical controls who underwent PD alone, patients who underwent surgery and adjuvant chemoradiation had significantly longer survival (36.9 months vs. 22 months; p < 0.05). Overall survival was significantly longer for both lymph node negative and lymph node positive patients (p < 0.05).
  
  
  CONCLUSIONS
  Adjuvant chemoradiation after PD for adenocarcinoma of the DCBD may improve local control and overall survival. The predominant mode of failure is distant metastatic disease, highlighting the need for improved systemic therapy.
authors.affiliation: Therapeutic Radiologists, Inc., Kansas City, MO, USA. michaelaaronhughes@gmail.com
authors.forename: Michael A
authors.initials: MA
authors.lastname: Hughes
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Frassica
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Yeo
authors.forename: Taylor S
authors.initials: TS
authors.lastname: Riall
authors.forename: Keith D
authors.initials: KD
authors.lastname: Lillemoe
authors.forename: John L
authors.initials: JL
authors.lastname: Cameron
authors.forename: Ross C
authors.initials: RC
authors.lastname: Donehower
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Laheru
authors.forename: Ralph H
authors.initials: RH
authors.lastname: Hruban
authors.forename: Ross A
authors.initials: RA
authors.lastname: Abrams
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003138:Common Bile Duct Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D016577:Pancreaticoduodenectomy; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil